Daniel Ben-Mordechay: Portal Vein Thrombosis – Ultrasound Perspective
Daniel Ben-Mordechay, Chief Executive Officer at Orimed GTD, shared a post on LinkedIn:
“Portal Vein Thrombosis (PVT): Ultrasound Perspective
Portal vein thrombosis is a key cause of prehepatic portal hypertension, resulting from partial or complete obstruction of the portal vein lumen by thrombus formation.
Clinically, PVT may be asymptomatic, particularly in chronic settings, and is often detected incidentally during imaging follow-up in patients with underlying liver disease.
However, in acute cases, it may present with abdominal pain or signs related to mesenteric venous involvement.
From an imaging standpoint, multiple modalities can be used for diagnosis and characterization, including CT and MRI.
Nevertheless, ultrasound remains the first-line imaging modality due to its availability, safety, and real-time assessment capabilities.
Ultrasound findings:
- Gray-scale imaging
Acute PVT typically appears as echogenic or heterogeneous material within the portal vein lumen. The vein may appear distended compared to normal, especially in early stages.
- Color Doppler evaluation
The hallmark finding is partial or complete absence of flow within the portal vein. In some cases, reduced or altered flow patterns may be observed rather than complete absence.
- Chronic PVT considerations
In longstanding cases, cavernous transformation may develop, characterized by multiple serpiginous collateral vessels replacing the normal portal vein.
From a POCUS perspective, recognizing the combination of intraluminal material and absent or abnormal Doppler flow is critical for raising suspicion and prompting further evaluation.
Early identification has direct clinical implications, particularly in guiding anticoagulation, evaluating underlying etiologies, and preventing complications such as portal hypertension and bowel ischemia.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause